Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-06
2007-03-06
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S306400
Reexamination Certificate
active
10469834
ABSTRACT:
This invention relates to the use of compounds of Formula (I) as vascular damaging agents: wherein X is selected from: —O—, —S—, —S(O)—, —S(O2)—, —N(R5)—, —C(O)—, —C(O)N(R5)—, —N(R5)C(O)—, —S(O2)N(R5)—, or —N(R5)S(O2)—; R1is independently selected from: amino, halo, hydroxy, —OPO3H2, C1-4alkyl, or C1-4alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified; R2is selected from: hydrogen or C1-4alkyl; R3is selected from: hydrogen, halo, hydroxy, hydroxyC1-4alkyl, cyano, cyanoC1-4alkyl, carboxy, carboxyC1-4alkyl, C1-4alkanoyl, C1-4alkanoylC1-4alkyl, carbamoyl, carbamoylC1-4alkyl, C1-4alkoxy, C1-4alkoxycarbonyl, C1-4alkoxycarbonylC1-4alkyl, C1-4alkoxycarbonylamino, amino, N—C1-4alkylamino, NN-diC1-4alkylamino, aminoC1-4alkyl, N—C1-4alkylaminoC1-4alkyl, NN-diC1-4alkylaminoC1-4alkyl, ureido, or C1-4alkylureyleno; R4is independently selected from: C1-4alkyl, C1-4alkoxy or halo; R5is selected from: hydrogen or C1-4alkyl; n is 0 or 1; p is 0, 1, 2 or 3; and q is 0, 1 or 2; or a salt, pro-drug or solvate thereof. The invention also relates to novel compounds of Formula (I) and to processes for the preparation of compounds of Formula (I).
REFERENCES:
patent: 3975531 (1976-08-01), Welstead, Jr. et al.
patent: 4006161 (1977-02-01), Holmes et al.
patent: 4045576 (1977-08-01), Welstead, Jr. et al.
patent: 4182774 (1980-01-01), Welstead, Jr. et al.
patent: 4472433 (1984-09-01), Ueda et al.
patent: 4503073 (1985-03-01), Walsh et al.
patent: 4710510 (1987-12-01), Mertens et al.
patent: 4725616 (1988-02-01), Kadin
patent: 4791129 (1988-12-01), Kadin
patent: 4810801 (1989-03-01), Mertens et al.
patent: 4904575 (1990-02-01), Ono et al.
patent: 5047554 (1991-09-01), Ehrgott et al.
patent: 5290802 (1994-03-01), Ehrgott et al.
patent: 5310935 (1994-05-01), Brossi et al.
patent: 5382593 (1995-01-01), Le Baut et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5849756 (1998-12-01), Burger et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 5973165 (1999-10-01), Kuo et al.
patent: 5998463 (1999-12-01), Hulin et al.
patent: 6114371 (2000-09-01), Tang et al.
patent: 6174883 (2001-01-01), Ehrgott et al.
patent: 6225335 (2001-05-01), Tang et al.
patent: 2001/0027207 (2001-10-01), Tang et al.
patent: 339294 (1977-10-01), None
patent: 7509773 (1977-02-01), None
patent: 8659847 (1987-04-01), None
patent: 2159362 (1971-11-01), None
patent: 199 40 829 (2001-03-01), None
patent: 1 432 576 (1976-04-01), None
patent: 0 003 771 (1979-09-01), None
patent: 1 560 007 (1980-01-01), None
patent: 0 008 226 (1980-02-01), None
patent: 0 022 317 (1981-01-01), None
patent: 2 098 208 (1982-11-01), None
patent: 0 153 818 (1985-09-01), None
patent: 0 155 828 (1985-09-01), None
patent: 0 164 860 (1985-12-01), None
patent: 0 175 551 (1986-03-01), None
patent: 0 181 136 (1986-05-01), None
patent: 0 221 753 (1987-05-01), None
patent: 0 249 407 (1987-12-01), None
patent: 0 255 178 (1988-02-01), None
patent: 0 350 163 (1990-01-01), None
patent: 0 375 451 (1990-06-01), None
patent: 0 393 936 (1990-10-01), None
patent: 0 213 984 (1991-01-01), None
patent: 0 438 796 (1991-07-01), None
patent: 0 445 467 (1991-09-01), None
patent: 0 459 133 (1991-12-01), None
patent: 0 503 349 (1992-09-01), None
patent: 0 275 762 (1993-11-01), None
patent: 0 636 608 (1994-07-01), None
patent: 0 673 937 (1995-09-01), None
patent: 0 760 239 (1997-03-01), None
patent: 0 788 890 (1997-08-01), None
patent: 0 978 279 (2000-02-01), None
patent: 1 136 071 (2001-09-01), None
patent: 1 258 252 (2002-11-01), None
patent: 2 042 541 (1980-09-01), None
patent: 2 055 820 (1981-03-01), None
patent: 2 105 708 (1983-03-01), None
patent: 2 253 848 (1992-09-01), None
patent: 2 272 439 (1994-05-01), None
patent: 48666 (1979-09-01), None
patent: 2000309534 (2000-11-01), None
patent: WO-91/09598 (1991-07-01), None
patent: WO-92/16524 (1992-10-01), None
patent: WO-93/12085 (1993-06-01), None
patent: WO-93/15051 (1993-08-01), None
patent: WO-94/05634 (1994-03-01), None
patent: WO-94/13663 (1994-06-01), None
patent: WO-94/18169 (1994-08-01), None
patent: WO-94/27963 (1994-12-01), None
patent: WO-94/29272 (1994-12-01), None
patent: WO-95/07276 (1995-03-01), None
patent: WO-95/14667 (1995-06-01), None
patent: WO-96/02508 (1996-02-01), None
patent: WO-96/02537 (1996-02-01), None
patent: WO-96/40116 (1996-12-01), None
patent: WO-97/06140 (1997-02-01), None
patent: WO-97/11056 (1997-03-01), None
patent: WO-97/42187 (1997-11-01), None
patent: WO-98/49127 (1998-11-01), None
patent: WO-98/50356 (1998-11-01), None
patent: WO-99/10325 (1999-03-01), None
patent: WO-99/48868 (1999-09-01), None
patent: WO-99/65875 (1999-11-01), None
patent: WO-99/61422 (1999-12-01), None
patent: WO-00/08202 (2000-02-01), None
patent: WO-00/12084 (2000-03-01), None
patent: WO-00/24396 (2000-05-01), None
patent: 00/41669 (2000-07-01), None
patent: WO-00/54810 (2000-09-01), None
patent: WO-00/56709 (2000-09-01), None
patent: WO-01/56710 (2000-09-01), None
patent: WO-00/59880 (2000-10-01), None
patent: WO-01/02394 (2001-01-01), None
patent: WO-01/37820 (2001-05-01), None
patent: WO-01/47517 (2001-07-01), None
patent: WO-01/047884 (2001-07-01), None
patent: WO-01/57019 (2001-08-01), None
patent: WO-01/60814 (2001-08-01), None
patent: WO-01/64681 (2001-09-01), None
patent: WO-01/68055 (2001-09-01), None
patent: WO-01/072708 (2001-10-01), None
patent: WO-01/94312 (2001-12-01), None
Murata, S., et al., “Absorption, Distribution, Metabolism, and Excretion of Amfenac Sodium IV. Metabolic Fate in Man, Rat and Dog,” Iyakuhin Kenkyu, 16(4), 769-783 (1985).
Isaka, M., et al., “Ocular Tissue Distribution in Rabbit after Instillation of Bromfenac Sodium Ophthalmic Solution,” Yakubutsu Dotal, 14(1), 32-41 (1999).
Lewer, P., “Preparation of 7-Hydroxy-2-oxoindolin-3-ylacetic Acid and its [13C2], [5-nt-3H], and [5-n-3H]-7-O-Glucosyl Analogues for Use in the Study of Indol-3-yl-acetic Acid Catabolism,” J. Chem. Soc. Perkin Trans., 1(4), 753-757 (1987).
Kametani, T., et al., “Studies on the Syntheses of Hetercyclic Compounds. Part 865. A Novel Synthesis of Indole Derivatives by Intramolecular Nucleophilic Aromatic Substitution,” J. Chem. Soc. Perkin, 1(1), 290-294 (1981).
Baxter, I., et al., “The Oxidation of 5-Arylsulphonamido-3,3-dimethyloxindoles and Related Compounds,” J. Chem. Soc. (C), 952-955 (1971).
Kametani, T., et al., “Synthesis of 1-Benzyloxindole Derivatives for the Study of Phenolic Oxidative Coupling (Studies on the Syntheses of Hyterocyclic Compounds. CCCXLVII,” Chem. Pharm. Bull., 18(4), 645-650 (1970).
Kametani, T., et al., “A Novel Synthesis of Indole Derivatives,” Heterocycles, 14(3), 277-280 (1980).
Lo, Y. S., et al., “Synthesis of 2-Amino-3-benzoylphenylacetic Acid,” J. Heterocyclic Chem., 17, 1663-1664 (1980).
Goetz, F., et al., “Ring-Chain Tautomerism in Anions Derived from Substituted (Arylideneamino)toluenes and (Arylideneamino)oxindoles,” J. Org. Chem., 48, 2468-2472 (1983).
Owa, T., et al., “A Focused Compound Library of Novel N-(7-Indolyl)benzenesulfonamides for the Discovery of Potent Cell Cycle Inhibitors,” Bioorganic & Medicinal Chemistry Letters, 10, 1223-1226 (2000).
Walsh, D., et al., “Antiinflammatory Agents. 3. Synthesis and Pharmacological Evaluation of 2-Amino-3-benzoylphenylacetic Acid and Analogues,” J. Med. Chem., 27(11), 1379-1388 (1984).
Kraynack, E., et al., “An Improved Procedure for the Regiospecific Synthesis of Electron Deficient 4- and 6-Substituted Isatins,” Tetrahedron Letters, 39, 7679-7682 (1998).
Walsh, D., et al., “Antiinflammatory Agents. 2. Syntheses and Antiinflammatory Activity of Substituted 2-Aminophenylacetic Acid Derivatives,&#x
AstraZeneca AB
Lambkin Deborah C.
LandOfFree
Indolone derivatives having vascular damaging activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolone derivatives having vascular damaging activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolone derivatives having vascular damaging activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3732780